John D. Bradley

John D. Bradley

Managing Director

New York Office  |   |   212.257.5805

John Bradley, a Managing Director at Torreya, works with the firm’s financing and M&A businesses. John has a vast network of relationships in the life sciences industry, as well as with family offices and high net worth individuals worldwide. An expert in branded pharmaceuticals and drug delivery, he has raised over $500 million in public and private capital for many pharmaceutical, insurance, and technology companies.

John has more than 40 years of corporate finance experience as an executive within both pharmaceutical companies and investment banks. He has also managed the assets of several large family offices.

His career highlights prior to joining Torreya in 2008 include Co-Founder and Chairman of the Board of Mystic Pharmaceuticals; Founder and Chairman of VentureLink; early-stage financings of many pharmaceutical companies, including Watson Pharmaceuticals (now part of Allergan Pharma), Ethical Holdings, Ltd., Caraco Pharmaceuticals (now part of Sun Pharma), and Lemmon Pharmacal, Inc. (now part of Teva Pharmaceuticals, Inc.); and President and Founder of Bradley-Hummel & Co., Inc., a NYSE member firm. Earlier in his career, he held positions at Brown Brothers Harriman and Drexel Burnham Lambert & Co.

John is a senior advisor to the New York Center for Living – Rehabilitation Center for Adolescents and Young Adults.

Selected Transactions

License of NOV03
in North America to
Bausch Health
December 2019
Mid-Atlantic Dental Partners
Credit facility from
$70 million
January 2019
Majority recap by
Hildred Capital Partners
March 2018
Crown Laboratories
Sale of
majority equity stake to
December 2017
Advisory to ownership group on sale to
March 2016
Rubicon Research
Sale of equity stake to
Everstone Group
$33 million
November 2016
Cambrooke Therapeutics
Preferred equity investment
$7 million
January 2016
Senior term loan
$15 million
December 2015
Canterbury Laboratories
Merger into
September 2013
Molecular Insight
Sale for up to
$106 million to
$12 million +
January 2013